A multicenter randomized controlled clinical study of Qishao Tianxin prescription in the treatment of early urinary incontinence after radical prostatectomy for prostate cancer.
Phase 1
Recruiting
- Conditions
- rinary incontinence
- Registration Number
- ITMCTR2100004503
- Lead Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
From January 2020 to June 2023, patients aged 55-75 who are prepared for radical resection of prostate cancer are mainly middle-to-high-risk prostate cancer patients:
(1) PSA >= 10; Or 4<=PSA<=10 and F/T < 0.16;
(2) TNM stage of prostate cancer >= T2 stage;
(3) Gleason score >= 7 points;Or the puncture Gleason score of both lobes >= 6 points at the same time; informed and agreed to participate in the clinical trial; able to cooperate with the treatment and complete the follow-up.
Exclusion Criteria
Patients with heart, brain and lung diseases or liver and renal insufficiency.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Qmax;Residual urine;
- Secondary Outcome Measures
Name Time Method OABSS;ICS-Q-SF;One hour urine pad test;prostate-specific antigen;urine routines;Urinary Incontinence Quality of Life Questionnaire;